News
The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.
FEATURED STORIES
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
The battle between bluebird bio and Errant Gene Therapeutics has escalated into a patent lawsuit. Errant alleges that bluebird’s gene therapies infringe on their patents for recombinant vectors.
If the panel votes in favor of the vaccine for children, it will move to the U.S. CDC. If both agencies support the data, children this age would be likely to receive their first shots in early November.
Initial results showed a strong neutralizing antibody response and favorable safety profile among the participants.
Sio Gene Therapies had a few big announcements last week, including a Fast Track Designation from the U.S. Food and Drug Administration and the reorganization of its R&D group.
Janssen reported analyses in which STELARA is showing promising results as a first-line therapy for Crohn’s Disease (CD) and Ulcerative Colitis (UC).
Some fear potential side effects, and more just aren’t sure about the quality and risks associated with a vaccine developed in an unprecedented nine months.
The concept is based on scientific studies showing that modulating the gut microbiome affects human health in multiple ways, beyond the expected gastrointestinal effects.
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
This is after the company shared positive results from its Phase III trial on Imfinzi, increasing the chances for survival in BTC patients when combined with standard-of-care chemotherapy regimens.
The U.S. Food and Drug Administration posted analyses of the Pfizer-BioNTech COVID-19 vaccine in children ages 5 to 11 years old ahead of Tuesday’s vaccines advisory committee meeting.